• Offer of up to 596,440 shares to private investors at a price of 33.50 euro per share
• Subscription period is expected to end on 11 November 2015
Hennigsdorf, 29 October 2015 – In the course of the ongoing capital increase of Deutsche Biotech Innovative AG (“DBI AG”) private investors can now for the first time subscribe for the company's shares. After expiry of the subscription period for existing shareholders on 28 October, the subscription period for private investors is expected to run until and including 11 November 2015.
In the context of the public offering of up to 596,400 new shares, DBI AG aims to raise proceeds of up to 20 million euro. By stating the ISIN DE000A0Z25L1 or the Securities Identification No. (WKN) A0Z25L, interested investors can subscribe new shares of DBI AG at a price of 33.50 euro through their local or custodian bank, the order function of several online banks as well as the subscribtion through the subscription platform of Wertpapierhandelsbank SCHNIGGE AG www.zeichnungsplattform.de.
DBI AG, whose shares are already listed on the Primary Market of the Düsseldorf Stock Exchange, aims at a dual listing on the Entry Standard of the Frankfurt Stock Exchange.
Financing of the attractive product pipeline
DBI AG plans to use the net proceeds from the capital increase for the further financing of the preclinical and clinical development of its three current drug candidates in the indications of sepsis and cancer and a diagnostic agent for the early diagnosis of urinary tract infections. In case of the full placement, the funds are expected to suffice until the first sale of an active agent to a pharmaceutical company and thus until the first proceeds from the DBI AG pipeline. This first exit is expected to be realized in 2018/2019. DBI AG’s business model foresees for the drugs to be sold or out-licensed whilst they are still being clinically developed, typically during or after a phase II trial.
The lead product is the patented drug Adrecizumab to reduce mortality by organic failure in septic shock. Although each year approximately 8 million people die of it, there is currently no approved drug worldwide. Adrecizumab has successfully passed the preclinical phase and will be tested in a Phase I trial as from the end of 2015.
Further information:
ISIN: DE000A0Z25L1
Securities Identification No. (WKN): A0Z25L
Ticker Symbol: VUA
Stock market segment: Primary Market Düsseldorf Stock Exchange
A current research study on DBI from First Berlin Equity Research is available on the Deutsche Biotech Innovativ AG website via the following link:
http://www.dbi-ag.de/investoren-presse/aktie/#anchor_d0823b06_Research-Reports
The BaFin-approved prospectus is also available on the website: http://www.dbi-ag.de/investoren-presse/kapitalerhoehung-2015/
About Deutsche Biotech Innovativ AG
Deutsche Biotech Innovativ AG is a biotechnology company that uses innovative blood biomarkers to research and clinically develop unique therapies for serious diseases lacking adequate medical treatment options. Its focus is on drugs for sepsis and cancer. The company's main product is Adrecizumab, a patented drug to reduce mortality due to organ failure in septic shock. Adrecizumab has successfully completed the preclinical phase and will be tested in a Phase I study starting end of 2015.
DBI AG aims to further expand its drug pipeline and invest in the research and development of drugs with high unique-selling-point potential. Both members of DBI AG's Management Board, Dr Bernd Wegener and Dr. Andreas Bergmann, have many years of experience in the biotechnology field. Both were founders and part of the management team of B.R.A.H.M.S. AG, a highly successful biotechnology company specialized in blood biomarkers. It was sold in 2009 for around 330 million euro. Dr. Bernd Wegener is also a member of the Executive Board of the Association of the German Pharmaceutical Industry (Bundesverband der Pharmazeutischen Industrie).
For more information, please contact:
Deutsche Biotech Innovativ AG
Ms. Susanne Wallace
Tel.: +49 (0)3302 20 77 811
Email: s.wallace@dbi-ag.de
Kirchhoff Consult AG
Ms. Anja Ben Lekhal
Tel.: +49 (0)40 609 186 55
Email: anja.benlekhal@kirchhoff.de
Help employers find you! Check out all the jobs and post your resume.
• Subscription period is expected to end on 11 November 2015
Hennigsdorf, 29 October 2015 – In the course of the ongoing capital increase of Deutsche Biotech Innovative AG (“DBI AG”) private investors can now for the first time subscribe for the company's shares. After expiry of the subscription period for existing shareholders on 28 October, the subscription period for private investors is expected to run until and including 11 November 2015.
In the context of the public offering of up to 596,400 new shares, DBI AG aims to raise proceeds of up to 20 million euro. By stating the ISIN DE000A0Z25L1 or the Securities Identification No. (WKN) A0Z25L, interested investors can subscribe new shares of DBI AG at a price of 33.50 euro through their local or custodian bank, the order function of several online banks as well as the subscribtion through the subscription platform of Wertpapierhandelsbank SCHNIGGE AG www.zeichnungsplattform.de.
DBI AG, whose shares are already listed on the Primary Market of the Düsseldorf Stock Exchange, aims at a dual listing on the Entry Standard of the Frankfurt Stock Exchange.
Financing of the attractive product pipeline
DBI AG plans to use the net proceeds from the capital increase for the further financing of the preclinical and clinical development of its three current drug candidates in the indications of sepsis and cancer and a diagnostic agent for the early diagnosis of urinary tract infections. In case of the full placement, the funds are expected to suffice until the first sale of an active agent to a pharmaceutical company and thus until the first proceeds from the DBI AG pipeline. This first exit is expected to be realized in 2018/2019. DBI AG’s business model foresees for the drugs to be sold or out-licensed whilst they are still being clinically developed, typically during or after a phase II trial.
The lead product is the patented drug Adrecizumab to reduce mortality by organic failure in septic shock. Although each year approximately 8 million people die of it, there is currently no approved drug worldwide. Adrecizumab has successfully passed the preclinical phase and will be tested in a Phase I trial as from the end of 2015.
Further information:
ISIN: DE000A0Z25L1
Securities Identification No. (WKN): A0Z25L
Ticker Symbol: VUA
Stock market segment: Primary Market Düsseldorf Stock Exchange
A current research study on DBI from First Berlin Equity Research is available on the Deutsche Biotech Innovativ AG website via the following link:
http://www.dbi-ag.de/investoren-presse/aktie/#anchor_d0823b06_Research-Reports
The BaFin-approved prospectus is also available on the website: http://www.dbi-ag.de/investoren-presse/kapitalerhoehung-2015/
About Deutsche Biotech Innovativ AG
Deutsche Biotech Innovativ AG is a biotechnology company that uses innovative blood biomarkers to research and clinically develop unique therapies for serious diseases lacking adequate medical treatment options. Its focus is on drugs for sepsis and cancer. The company's main product is Adrecizumab, a patented drug to reduce mortality due to organ failure in septic shock. Adrecizumab has successfully completed the preclinical phase and will be tested in a Phase I study starting end of 2015.
DBI AG aims to further expand its drug pipeline and invest in the research and development of drugs with high unique-selling-point potential. Both members of DBI AG's Management Board, Dr Bernd Wegener and Dr. Andreas Bergmann, have many years of experience in the biotechnology field. Both were founders and part of the management team of B.R.A.H.M.S. AG, a highly successful biotechnology company specialized in blood biomarkers. It was sold in 2009 for around 330 million euro. Dr. Bernd Wegener is also a member of the Executive Board of the Association of the German Pharmaceutical Industry (Bundesverband der Pharmazeutischen Industrie).
For more information, please contact:
Deutsche Biotech Innovativ AG
Ms. Susanne Wallace
Tel.: +49 (0)3302 20 77 811
Email: s.wallace@dbi-ag.de
Kirchhoff Consult AG
Ms. Anja Ben Lekhal
Tel.: +49 (0)40 609 186 55
Email: anja.benlekhal@kirchhoff.de
Help employers find you! Check out all the jobs and post your resume.
